CLOs on the Move

Regor Therapeutics

www.regor.com

 
Founded in 2018 by a team of accomplished scientists with a proven track record in drug discovery and executive leadership in top global biopharmaceutical companies, Regor is a pioneering international biotech company with headquarters in Shanghai, China; Boston and San Diego, USA.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.regor.com
  • 50 Soldiers Field Pl
    Boston, MA USA 02135
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Apple Valley Chamber-commerce

Apple Valley Chamber-commerce is a Apple Valley, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

VLST

VLST is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OriGene Technologies

OriGene Technologies is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. We are focusing the initial development of our VDC technology platform to treat tumors of high unmet need in ocular and urologic oncology. Belzupacap sarotalocan (bel-sar), our first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved. Beyond early-stage choroidal melanoma, we are developing bel-sar in additional ocular oncology indications, including choroidal metastasis. Leveraging our VDCs` broad tumor targeting capabilities, we have also initiated a clinical program in non-muscle invasive bladder cancer, or NMIBC, our first non-ocular solid tumor indication.